Biologics are incredibly powerful and targeted. For these reasons, pharmaceutical companies have invested a lot of time and money over the past 20 years developing medications based on these ...

Adbry is a new biologic therapy specifically developed for patients with moderate to severe atopic dermatitis (eczema). The treatment is a monoclonal antibody that neutralizes interleukin-13 (IL ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

Takeda has bought US biotech PvP Biologics for $330 million, adding a potential new form of therapy for coeliac disease to its pipeline. The Japanese pharma decided to buy San Diego-based PvP ...

Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that CEO ...

Study highlights barriers to care, treatment preferences, and interest in research participation in psoriasis in the Latine ...

BRIDGEWATER, N.J., and BENGALURU, India, Jan. 9, 2025 /PRNewswire/ --Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: ...

After hours: January 10 at 7:29:13 PM EST Loading Chart for TSBX ...

Some other medicines that are slated to become blockbusters in the near future include GSK’s vaccine candidate GSK-3536819 ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...